头孢地尔罗与对照药物对癌症患者分离株的活性。
Activity of Cefiderocol and Comparators against Isolates from Cancer Patients.
机构信息
Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
出版信息
Antimicrob Agents Chemother. 2020 Apr 21;64(5). doi: 10.1128/AAC.01955-19.
Abstract
Cefiderocol inhibited 97.5% of 478 Gram-negative isolates from cancer patients at ≤4 mg/liter. It had potent activity against extended-spectrum β-lactamase-positive , carbapenem-resistant (CRE), and nonfermenting Gram-negative bacilli, including , , and species isolates. Amikacin, ceftazidime-avibactam, and meropenem had appreciable activity against non-CRE No comparators were active against multidrug-resistant isolates. Only trimethoprim-sulfamethoxazole had appreciable activity against isolates. Overall, cefiderocol was associated with the lowest level of resistance.
摘要
头孢地尔在 ≤4 毫克/升时抑制了 478 株来自癌症患者的革兰氏阴性菌的 97.5%。它对产超广谱β-内酰胺酶阳性、碳青霉烯类耐药（CRE）和非发酵革兰氏阴性杆菌具有强大的活性，包括肠杆菌科、铜绿假单胞菌和不动杆菌属的分离株。阿米卡星、头孢他啶-阿维巴坦和美罗培南对非 CRE 的分离株具有相当的活性。没有比较药物对多药耐药的分离株具有活性。只有复方磺胺甲噁唑对分离株具有相当的活性。总的来说，头孢地尔的耐药率最低。
相似文献
1
Activity of Cefiderocol and Comparators against Isolates from Cancer Patients.头孢地尔罗与对照药物对癌症患者分离株的活性。
Antimicrob Agents Chemother. 2020 Apr 21;64(5). doi: 10.1128/AAC.01955-19.
2
Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.头孢地尔：一种具有抗碳青霉烯类和多药耐药革兰氏阴性杆菌活性的铁载体头孢菌素。
Drugs. 2019 Feb;79(3):271-289. doi: 10.1007/s40265-019-1055-2.
3
In vitro activities of cefiderocol, ceftolozane/tazobactam, ceftazidime/avibactam and other comparative drugs against imipenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, and Stenotrophomonas maltophilia, all associated with bloodstream infections in Taiwan.在体外研究中，头孢地尔、头孢他唑巴坦/他唑巴坦、头孢他啶/阿维巴坦和其他比较药物对耐亚胺培南铜绿假单胞菌和鲍曼不动杆菌以及嗜麦芽窄食单胞菌的活性，这些细菌均与台湾的血流感染有关。
J Antimicrob Chemother. 2019 Feb 1;74(2):380-386. doi: 10.1093/jac/dky425.
4
Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia.头孢地尔罗对多重耐药肠杆菌科、鲍曼不动杆菌、铜绿假单胞菌和嗜麦芽窄食单胞菌高危克隆的活性。
J Antimicrob Chemother. 2020 Jul 1;75(7):1840-1849. doi: 10.1093/jac/dkaa117.
5
In vitro activity of cefiderocol against carbapenemase-producing and meropenem-non-susceptible Gram-negative bacteria collected in the Japan Antimicrobial Resistant Bacterial Surveillance.在日本抗菌药物耐药性细菌监测中收集的产碳青霉烯酶和对美罗培南不敏感的革兰氏阴性菌的体外活性研究。
J Glob Antimicrob Resist. 2024 Sep;38:12-20. doi: 10.1016/j.jgar.2024.05.009. Epub 2024 May 22.
6
In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated by Clinical Laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015.2015-2016 年北美和欧洲临床实验室分离的革兰氏阴性杆菌的体外药敏试验：SIDERO-WT-2015。
Int J Antimicrob Agents. 2019 Apr;53(4):456-466. doi: 10.1016/j.ijantimicag.2018.11.007. Epub 2018 Nov 22.
7
In vitro antimicrobial susceptibility of clinical respiratory isolates to ceftazidime-avibactam and comparators (2016-2018).临床呼吸道分离株对头孢他啶-阿维巴坦及对照药物的体外抗菌敏感性（2016 - 2018年）
BMC Infect Dis. 2021 Jun 23;21(1):600. doi: 10.1186/s12879-021-06153-0.
8
Verification of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Susceptibility Testing Methods against Carbapenem-Resistant Enterobacteriaceae and Pseudomonas aeruginosa.碳青霉烯类耐药肠杆菌科细菌和铜绿假单胞菌中头孢他啶-阿维巴坦和头孢唑南-他唑巴坦药敏检测方法的验证。
J Clin Microbiol. 2018 Jan 24;56(2). doi: 10.1128/JCM.01093-17. Print 2018 Feb.
9
In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study).头孢地尔罗的体外活性，一种铁载体头孢菌素，针对最近收集的临床相关碳青霉烯类药物不敏感的革兰氏阴性杆菌，包括丝氨酸碳青霉烯酶和金属β-内酰胺酶产生的分离株（SIDERO-WT-2014 研究）。
Int J Antimicrob Agents. 2019 Feb;53(2):177-184. doi: 10.1016/j.ijantimicag.2018.10.007. Epub 2018 Oct 26.
10
Activity of ceftolozane-tazobactam, ceftazidime-avibactam, meropenem-vaborbactam, cefiderocol and comparators against Gram-negative organisms causing bloodstream infections in Northern Italy (2019-2021): emergence of complex resistance phenotypes.在意大利北部，引起血流感染的革兰氏阴性菌对头孢洛扎他唑巴坦、头孢他啶-阿维巴坦、美罗培南-沃巴坦、头孢地尔和对照药物的活性（2019-2021 年）：复杂耐药表型的出现。
J Chemother. 2022 Sep;34(5):302-310. doi: 10.1080/1120009X.2022.2031471. Epub 2022 Jan 31.
引用本文的文献
1
Cefiderocol-resistant pathogens in German hospital wastewater: a reservoir for multidrug resistance.德国医院废水中对头孢地尔耐药的病原体：多重耐药性的一个储存库。
Sci Rep. 2025 Aug 27;15(1):31622. doi: 10.1038/s41598-025-17379-2.
2
Whole-genome analysis of NDM-producing associated with recurrent bacteraemia with rapid development of aztreonam-avibactam resistance.产NDM细菌的全基因组分析与复发性菌血症及氨曲南-阿维巴坦耐药性的快速发展相关。
Emerg Microbes Infect. 2025 Dec;14(1):2539193. doi: 10.1080/22221751.2025.2539193. Epub 2025 Aug 6.
3
Cefiderocol-Resistant Bacteremia Following WATCHMAN Implantation: A Case Report and Review of the Literature.WATCHMAN植入术后出现对头孢地尔耐药的菌血症：一例病例报告及文献综述
Case Rep Infect Dis. 2025 May 20;2025:5221364. doi: 10.1155/crdi/5221364. eCollection 2025.
4
Rare or Unusual Non-Fermenting Gram-Negative Bacteria: Therapeutic Approach and Antibiotic Treatment Options.罕见或不常见的非发酵革兰氏阴性菌：治疗方法与抗生素治疗选择
Antibiotics (Basel). 2025 Mar 16;14(3):306. doi: 10.3390/antibiotics14030306.
5
Updates on the Activity, Efficacy and Emerging Mechanisms of Resistance to Cefiderocol.头孢地尔的活性、疗效及新出现的耐药机制研究进展
Curr Issues Mol Biol. 2024 Dec 14;46(12):14132-14153. doi: 10.3390/cimb46120846.
6
Prevalence of colistin resistance in clinical isolates of : a systematic review and meta-analysis.临床分离株中黏菌素耐药性的流行情况：一项系统评价和荟萃分析。
Front Microbiol. 2024 Oct 9;15:1477836. doi: 10.3389/fmicb.2024.1477836. eCollection 2024.
7
Commercially available tests for determining cefiderocol susceptibility display variable performance in the Achromobacter genus.市售的用于检测头孢地尔罗酯药敏性的检测方法在不动杆菌属中表现出不同的性能。
Ann Clin Microbiol Antimicrob. 2024 Aug 22;23(1):78. doi: 10.1186/s12941-024-00731-1.
8
In vitro resistance development gives insights into molecular resistance mechanisms against cefiderocol.体外耐药性发展使人们深入了解对头孢地尔罗耐药的分子耐药机制。
J Antibiot (Tokyo). 2024 Nov;77(11):757-767. doi: 10.1038/s41429-024-00762-y. Epub 2024 Jul 30.
9
Cefiderocol for treating severe aerobic Gram-negative bacterial infections: technology evaluation to inform a novel subscription-style payment model.头孢地尔罗治疗严重需氧革兰氏阴性细菌感染：技术评估以提供一种新的订阅式支付模式。
Health Technol Assess. 2024 Jun;28(28):1-238. doi: 10.3310/YGWR4511.
10
Cefiderocol susceptibility of Achromobacter spp.: study of an accurately identified collection of 230 strains.嗜麦芽窄食单胞菌属对头孢地尔罗的药敏性：对 230 株准确鉴定的菌株的研究。
Ann Clin Microbiol Antimicrob. 2024 Jun 17;23(1):54. doi: 10.1186/s12941-024-00709-z.
本文引用的文献
1
Comparative Activities of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Enterobacteriaceae Isolates Producing Extended-Spectrum β-Lactamases from U.S. Hospitals.美国家庭医院产超广谱β-内酰胺酶肠杆菌科分离株的头孢他啶-阿维巴坦和头孢噻肟-他唑巴坦的比较活性。
Antimicrob Agents Chemother. 2019 Jun 24;63(7). doi: 10.1128/AAC.00160-19. Print 2019 Jul.
2
Stability of Novel Siderophore Cephalosporin S-649266 against Clinically Relevant Carbapenemases.新型铁载体头孢菌素S-649266对临床相关碳青霉烯酶的稳定性
Antimicrob Agents Chemother. 2016 Jun 20;60(7):4384-6. doi: 10.1128/AAC.03098-15. Print 2016 Jul.
3
The emerging problem of bacterial resistance in cancer patients; proceedings of a workshop held by MASCC "Neutropenia, Infection and Myelosuppression" Study Group during the MASCC annual meeting held in Berlin on 27-29 June 2013.癌症患者中日益凸显的细菌耐药性问题；MASCC“中性粒细胞减少、感染与骨髓抑制”研究小组在2013年6月27日至29日于柏林举行的MASCC年会上举办的研讨会会议记录
Support Care Cancer. 2016 Jul;24(7):2819-26. doi: 10.1007/s00520-016-3183-5. Epub 2016 Apr 20.
4
In vitro antimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria.S-649266，一种儿茶酚取代的铁载体头孢菌素，在测试时对非发酵革兰氏阴性菌的体外抗菌活性。
J Antimicrob Chemother. 2016 Mar;71(3):670-7. doi: 10.1093/jac/dkv402. Epub 2015 Dec 7.
5
In Vitro Antimicrobial Activity of a Siderophore Cephalosporin, S-649266, against Enterobacteriaceae Clinical Isolates, Including Carbapenem-Resistant Strains.一种铁载体头孢菌素S-649266对肠杆菌科临床分离株（包括耐碳青霉烯菌株）的体外抗菌活性
Antimicrob Agents Chemother. 2015 Nov 16;60(2):729-34. doi: 10.1128/AAC.01695-15. Print 2016 Feb.
6
"Stormy waters ahead": global emergence of carbapenemases.“波涛汹涌的前路”：碳青霉烯酶在全球的出现。
Front Microbiol. 2013 Mar 14;4:48. doi: 10.3389/fmicb.2013.00048. eCollection 2013.
7
Recent changes in bacteremia in patients with cancer: a systematic review of epidemiology and antibiotic resistance.癌症患者菌血症的近期变化：流行病学和抗生素耐药性的系统评价。
Eur J Clin Microbiol Infect Dis. 2013 Jul;32(7):841-50. doi: 10.1007/s10096-013-1819-7. Epub 2013 Jan 25.
8
Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america.抗菌药物在肿瘤中性粒细胞减少患者应用的临床实践指南：美国传染病学会 2010 年更新版。
Clin Infect Dis. 2011 Feb 15;52(4):e56-93. doi: 10.1093/cid/cir073.
Zotero 插件